» Articles » PMID: 35605625

Safety and Immunogenicity of Heterologous Boost Immunisation with an Orally Administered Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine in Chinese Adults: a Randomised, Open-label, Single-centre Trial

Abstract

Background: Due to waning immunity and protection against infection with SARS-CoV-2, a third dose of a homologous or heterologous COVID-19 vaccine has been proposed by health agencies for individuals who were previously primed with two doses of an inactivated COVID-19 vaccine.

Methods: We did a randomised, open-label, controlled trial to evaluate the safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in Chinese adults (≥18 years old) who had previously received two doses of an inactivated SARS-CoV-2 vaccine-Sinovac CoronaVac. Eligible participants were randomly assigned (1:1:1) to receive a heterologous booster vaccination with a low dose (1·0 × 10 viral particles per mL; 0·1 mL; low dose group), or a high dose (1·0 × 10 viral particles per mL; 0·2 mL; high dose group) aerosolised Ad5-nCoV, or a homologous intramuscular vaccination with CoronaVac (0·5 mL). Only laboratory staff were masked to group assignment. The primary endpoint for safety was the incidence of adverse reactions within 14 days after the booster dose. The primary endpoint for immunogenicity was the geometric mean titres (GMTs) of serum neutralising antibodies (NAbs) against live SARS-CoV-2 virus 14 days after the booster dose. This study was registered with ClinicalTrials.gov, NCT05043259.

Findings: Between Sept 14 and 16, 2021, 420 participants were enrolled: 140 (33%) participants per group. Adverse reactions were reported by 26 (19%) participants in the low dose group and 33 (24%) in the high dose group within 14 days after the booster vaccination, significantly less than the 54 (39%) participants in the CoronaVac group (p<0·0001). The low dose group had a serum NAb GMT of 744·4 (95% CI 520·1-1065·6) and the high dose group had a GMT of 714·1 (479·4-1063·7) 14 days after booster dose, significantly higher than the GMT in the CoronaVac group (78·5 [60·5-101·7]; p<0·0001).

Interpretation: We found that a heterologous booster vaccine with an orally administered aerosolised Ad5-nCoV is safe and highly immunogenic in adults who have previously received two doses of CoronaVac as the primary series vaccination.

Funding: National Natural Science Foundation of China and Jiangsu Provincial Key Research and Development Program.

Citing Articles

Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection.

Worzner K, Schmidt S, Zimmermann J, Tami A, Polacek C, Fernandez-Antunez C EBioMedicine. 2025; 113:105615.

PMID: 39983329 PMC: 11893338. DOI: 10.1016/j.ebiom.2025.105615.


Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications.

Zhou M, Xiao H, Yang X, Cheng T, Yuan L, Xia N MedComm (2020). 2025; 6(2):e70056.

PMID: 39830020 PMC: 11739453. DOI: 10.1002/mco2.70056.


Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2.

Lin Y, Liao X, Cao X, Zhang Z, Wang X, He X J Clin Invest. 2025; 135(5).

PMID: 39808503 PMC: 11870729. DOI: 10.1172/JCI175233.


Respiratory delivered vaccines: Current status and perspectives in rational formulation design.

Wu L, Xu W, Jiang H, Yang M, Cun D Acta Pharm Sin B. 2025; 14(12):5132-5160.

PMID: 39807330 PMC: 11725141. DOI: 10.1016/j.apsb.2024.08.026.


Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China.

Wang K, Zeng T, Guo Z, Liang J, Sun S, Ni Y BMC Infect Dis. 2024; 24(1):1401.

PMID: 39695978 PMC: 11654266. DOI: 10.1186/s12879-024-10250-1.


References
1.
Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

2.
Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

3.
Sprangers M, Lakhai W, Koudstaal W, Verhoeven M, Koel B, Vogels R . Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003; 41(11):5046-52. PMC: 262545. DOI: 10.1128/JCM.41.11.5046-5052.2003. View

4.
Zhang W, Davis B, Chen S, Sincuir Martinez J, Plummer J, Vail E . Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA. 2021; 325(13):1324-1326. PMC: 7879386. DOI: 10.1001/jama.2021.1612. View

5.
Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View